62 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34480108 | Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. | 2022 Feb | 4 |
2 | 35201310 | Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. | 2022 Feb 1 | 1 |
3 | 33085221 | Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. | 2021 Jan | 1 |
4 | 33387367 | Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. | 2021 Oct | 1 |
5 | 33799050 | Oxycodone findings and CYP2D6 function in postmortem cases. | 2021 Jul | 2 |
6 | 34267337 | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). | 2021 Jul 15 | 2 |
7 | 34565798 | Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). | 2021 Sep 27 | 1 |
8 | 34575542 | Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism. | 2021 Sep 14 | 5 |
9 | 34581987 | Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels. | 2021 Dec | 4 |
10 | 34922356 | Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites using LC-MS/MS. | 2021 Dec 18 | 1 |
11 | 31925778 | Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions. | 2020 Feb | 3 |
12 | 29714124 | Clinical application of pharmacogenetics in pain management. | 2018 Mar | 1 |
13 | 29801577 | Pharmacogenetics in Pain Treatment. | 2018 | 1 |
14 | 30425549 | CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. | 2018 | 2 |
15 | 27692933 | Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. | 2017 Sep 10 | 1 |
16 | 28244808 | CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. | 2017 Mar | 4 |
17 | 28340451 | The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. | 2017 Apr | 1 |
18 | 28769582 | CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. | 2017 | 1 |
19 | 27388970 | The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. | 2016 Nov | 1 |
20 | 27702939 | Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis. | 2016 Oct | 1 |
21 | 24975450 | CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study. | 2015 Feb | 2 |
22 | 25948306 | [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients]. | 2015 | 1 |
23 | 26447442 | Pharmacogenetics: Using Genetic Information to Guide Drug Therapy. | 2015 Oct 1 | 1 |
24 | 24495562 | The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment. | 2014 Mar | 5 |
25 | 24517173 | Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. | 2014 May | 4 |
26 | 24523296 | Observations of urinary oxycodone and metabolite distributions in pain patients. | 2014 Apr | 1 |
27 | 25121773 | Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. | 2014 | 1 |
28 | 25518025 | Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. | 2014 Dec 17 | 1 |
29 | 23555934 | CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. | 2013 | 4 |
30 | 23588782 | Applications of CYP450 testing in the clinical setting. | 2013 Jun | 1 |
31 | 23605691 | Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. | 2013 May | 2 |
32 | 23783165 | Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. | 2013 Aug | 1 |
33 | 21735164 | Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. | 2012 Jan | 2 |
34 | 22148986 | Is maternal opioid use hazardous to breast-fed infants? | 2012 Jan | 1 |
35 | 22452458 | Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. | 2012 Jul | 2 |
36 | 22694279 | Preventing opioid-related deaths in children undergoing surgery. | 2012 Jul | 1 |
37 | 22747548 | Non-analgesic effects of opioids: interactions between opioids and other drugs. | 2012 | 1 |
38 | 23226064 | Pharmacogenomic considerations in opioid analgesia. | 2012 | 4 |
39 | 20857093 | Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. | 2011 Jan | 2 |
40 | 21173180 | Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. | 2011 Mar | 1 |
41 | 21174486 | Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. | 2011 Jan 1 | 1 |
42 | 21209234 | CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. | 2011 Nov | 2 |
43 | 19719813 | Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. | 2010 Feb | 3 |
44 | 19755414 | Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. | 2010 Jan | 1 |
45 | 20504256 | Personalized therapy in pain management: where do we stand? | 2010 Jun | 1 |
46 | 20590587 | The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. | 2010 Jun | 4 |
47 | 20590588 | Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. | 2010 Jun | 6 |
48 | 20642550 | Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. | 2010 Jul | 12 |
49 | 29913934 | Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients. | 2010 Jan 1 | 3 |
50 | 19281600 | The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. | 2009 Apr | 2 |